BioCardia: The Japan Clock Slips Again, and the Cash Clock Doesn't
A $12 million company is selling a 2028 approval story to investors while the Shonin submission quietly drifts out of 2026 — so management has opened a third front in gene-therapy delivery partnerships
BCDA · Earnings Call · 2026-11-12
The Submission That Keeps Moving Right
For three consecutive quarters, the central question put to BioCardia's management has been some version of the same thing: when does the CardiAMP Shonin application actually go into Japan? The answer has migrated, and this quarter it migrated again. In May, Peter Altman was explicit about the arithmetic: “we will complete the submission in roughly 7 months, I would expect” — Peter Altman, President and Chief Executive Officer · 2026-05-15 — implying a year-end 2026 filing, followed by roughly a 12-month review, which he framed as approval and market entry in Japan "in roughly 19 months." In August, an analyst asked directly whether the outstanding PMDA documentation requests “could push the Q4 2026 Shonin submission timeline as well” — Deepankar Roy, Analyst · 2026-08-12. Management disputed the substance but never reaffirmed the date. On Thursday, the date quietly dissolved:Read that against the same paragraph: approval is expected "12 months after we complete our Shonin submission." If "the coming months" lands in Q1 or Q2 of 2027, the Japanese revenue event — the thing the CEO himself calls “the main driver of significant value” — Peter Altman, President and Chief Executive Officer · 2026-11-12 — moves into 2028. Nothing broke. Everything simply took one more quarter, which is the defining rhythm of this company's relationship with its own timelines. The keyword record confirms this is a story of a process advancing, not a surprise. cell therapy in Japan is the company's second-ranked theme this quarter, but its ancestors — "approval in Japan," "post marketing study," "PMDA submission" — have run for six-plus quarters. What has genuinely rotated is the vocabulary: the old workhorse clinical consultation, once a top gainer, has been fading as a company theme now that the formal consultation is behind them, replaced at the top of the list by approval process and a concrete de novo approval pathway for the Helix catheter. That is a real transition in regulatory state — but it is a transition to a longer wait, not a nearer payday.We have answered all of these questions to Japan's Pharmaceuticals and Medical Devices Agency satisfaction, and we are proceeding to Shonin submission with our designated marketing authorization holder... The timing of this is fluid, but it looks like most tasks will be completed in the coming months.